東曜藥業-B:2023年年報
Dongyao Pharmaceutical-B announced that it will achieve revenue of 781 million yuan in 2023, a 77% year-on-year increase
Dongyao Pharmaceutical-B (01875) announced its 2023 results. The group's revenue was approximately RMB 781 million, an increase of 77% over the previous year. Among them, product sales revenue was RMB 630 million, an increase of 107% over the previous year. The main contribution came from a sharp increase in sales performance of the core product, Park Hsin Ting (bevacizumab injection). CDMO/CMO business revenue was RMB 141 million, up 94% year over year. Since there was no one-time authorization income for the full year of 2023 (RMB 54,151 million for the full year of 2022), excluding this factor, the revenue for the full year of 2023 is the same
Gelonghui Announcements Selected (Hong Kong Stocks) | Fuyao Glass (03606.HK) Announces Annual Results: Net Profit Increased by 18.37% to RMB 5.629 billion, with an estimated capital requirement of RMB 41,016 billion for the full year of 2024
[Today's Focus] Fuyao Glass (03606.HK) announced annual results: net profit increased by 18.37% to 5.629 billion yuan, with an estimated capital requirement of 41,016 billion yuan for 2024 Fuyao Glass (03606.HK) announced annual results. For the year ended December 31, 2023, the company consolidated revenue of RMB 33.161 billion, an increase of 18.02% over the same period of the previous year; achieved profit before tax of RMB 6.715 billion, an increase of 20.38% over the same period of the previous year, and achieved an annual profit of RMB 20.38% over the same period last year 5.629 billion yuan, compared to the previous year
Dongyao Pharmaceutical-B (01875.HK) announced annual results, a sharp increase in revenue of 77%, and the group's hematopoietic capacity continued to increase
Gelonghui March 15 | Dongyao Pharmaceutical-B (01875.HK) announced that in 2023, the Group's revenue was RMB 780,629 thousand, an increase of 77% over the previous year. Among them, product sales revenue was RMB 630,207 thousand, an increase of 107% over the previous year. The main contribution was due to a significant increase in sales performance of the core product Park Xinting (bevacizumab injection). CDMO/CMO business revenue was RMB 140,898 thousand, up 94% year over year. Due to no one-time authorization income for the full year of 2023 (RMB 54,151 thousand for the full year of 2022)
TOT BIOPHARM-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Dongyao Pharmaceutical-B (01875.HK) plans to hold a board meeting on March 15 to approve annual results
Gelonghui March 5 | Dongyao Pharmaceutical-B (01875.HK) announced that the company will hold a board meeting on March 15, 2024 (Friday) to consider and approve the Group's annual results for the year ended December 31, 2023, and to deal with other matters.
Changes in Hong Kong stocks | Dongyao Pharmaceutical-B (01875) is now up more than 8%, and overseas authorized transactions for domestic ADCs are hot
Dongyao Pharmaceutical-B (01875) is currently up more than 8%. As of press release, it is up 8.12% to HK$2.13.
Changes in Hong Kong stocks | Dongyao Pharmaceutical-B (01875) boosted by more than 23%, ADC innovation and development acceleration agencies previously recommended focusing on ADC CDMO innovative pharmaceutical companies, etc.
Dongyao Pharmaceutical-B (01875) rose more than 23%. As of press release, it was up 21.91% to HK$2.17, with a turnover of HK$2,496 million.
Dongyao Pharmaceutical-B [01875] is now reported at HK$2.17, an increase of 21.91%
As of 13:49, Dongyao Pharmaceutical-B [01875] reported HK$2.17, up HK$0.39 or 21.91% from last year's closing price, with a turnover of HK$170,500, today's highest price of HK$2.2, and the lowest price of HK$1.74. Based on yesterday's closing price, the 10-day average price is HK$1.90 and the 50-day average price is HK$1.90. The current price-earnings ratio is -20.34 times, and the 14-day strength index is 33.93.
Dongyao Pharmaceutical-B (01875.HK)'s revenue in the first three quarters increased 77% to 542 million yuan, and sales of self-developed products increased significantly
Gelonghui November 10 | Dongyao Pharmaceutical-B (01875.HK) announced that in the nine-month period ending September 30, 2023, the Group's revenue increased 77% year-on-year to RMB 542 million, mainly due to the sharp increase in sales of self-developed products and the rapid increase in CDMO/CMO business.
Huajin Securities: ADC innovation and development accelerates focus on Rongchang Biotech (688331.SH) and other related targets
Huajin Securities released a research report saying that due to the complex design of ADC structures, technology platforms are the primary competitive barrier for innovative pharmaceutical companies.
Changes in Hong Kong stocks | Dongyao Pharmaceutical-B (01875) rose nearly 10%, core product sales revenue increased sharply in the first half of the year, and the CDMO sector continued to rise
Dongyao Pharmaceutical-B (01875) rose nearly 10%. As of press release, it rose 9.94% to HK$1.99 billion, with a total market value of HK$1,538 billion.
TOT BIOPHARM-B: INTERIM REPORT 2023
Dongyao Pharmaceutical-B (01875) Interim Report - Revenue Maintains Triple-Digit Growth
Dongyao Pharmaceutical-B (01875) announced its 2023 interim results. Total revenue for the first half of the year was RMB 328 million, an increase of 80% over the previous year. Excluding the impact of license revenue for the first half of 2022, the revenue growth rate reached 147% year-on-year.
Exploring the dark horse in the ADC CDMO field: Dongyao Pharmaceutical's (01875.HK) performance explosion draws attention
The high increase in revenue and the correction in net cash flow from operating activities clearly depict the company's remarkable achievements in the CDMO field.
TOT Biopharm's Loss Narrows in H1
TOT Biopharm International (HKG:1875) incurred a loss attributable to shareholders of 15.2 million yuan for the first half, narrowing from the year-ago attributable loss of 15.7 million yuan. Loss per
Dongyao Pharmaceutical-B Announces Liu Weidong Appointment as Non-Executive Director
Dongyao Pharmaceutical-B (01875) announced that Qiu Yumin has resigned as the company's non-executive director, chairman of the remuneration committee, and a member of the Audit and Related Party Transaction Review Committee and Strategy and ESG Committee due to the need to concentrate more energy on handling other businesses, all effective from August 12, 2023. Mr. Qiu will also resign as a director of Dongyao Pharmaceutical Co., Ltd. (Suzhou Dongyao), a wholly-owned subsidiary of the company, in due course. In addition, Liu Weidong has been appointed as the company's non-executive director, chairman of the remuneration committee, and a member of the Audit and Related Party Transactions Review Committee and Strategy and ESG Committee, all since 2023
Dongyao Pharmaceutical-B announced interim results and achieved revenue of 328 million yuan, an 80% year-on-year increase
Dongyao Pharmaceutical-B (01875) announced its 2023 interim results. Operating revenue was RMB 328 million (same unit), an increase of 80% over the previous year. Excluding the impact of one-time licensing revenue for the first half of 2022, revenue increased 147% year-on-year. Among them, product sales revenue was about 278 million yuan, an increase of 167% over the previous year, mainly from the core product bevacizumab injection, the sales volume of paxindine, which continues to rise. CDMO/CMO business revenue reached RMB 46.546 million, up 105% year on year. New projects are expected to contribute more revenue to the group in the second half of the year. The group's cash
TOT BIOPHARM-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
Dongyao Pharmaceutical-B (01875.HK) will hold a board meeting on August 11 to approve interim results
On August 1, GLONGWI | Dongyao Pharmaceutical-B (01875.HK) announced that the company will hold a board meeting on August 11, 2023 to consider and approve the Group's interim results for the six months ended June 30, 2023, and to handle other matters.
No Data